(Total Views: 252)
Posted On: 05/31/2017 12:55:19 PM
Post# of 72446
B-OM is the likelier candidate for a similar deal, but CTIX can win from both ends.
With no extant preventive treatment for OM, the bar is lower for a safe drug.
Leo et. al. are - in fact absolutely need to be - pursuing a deal based on these and the prurisol trial. The stats generated from these mid-stage trials likewise need to be convincing and unimpeachable. . . and not seem like a contortion of subsets or p-values in groping for a success. That said, the interim data, sans the highest dose arms, points to very favorable outcomes pending safety tolerance on the higher doses. So I agree with the cha-ching evaluation here and have been adding considerably.
With no extant preventive treatment for OM, the bar is lower for a safe drug.
Leo et. al. are - in fact absolutely need to be - pursuing a deal based on these and the prurisol trial. The stats generated from these mid-stage trials likewise need to be convincing and unimpeachable. . . and not seem like a contortion of subsets or p-values in groping for a success. That said, the interim data, sans the highest dose arms, points to very favorable outcomes pending safety tolerance on the higher doses. So I agree with the cha-ching evaluation here and have been adding considerably.
(0)
(0)
